SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 1, 2009, Pages 26-31

  Huang, Sheng Wen ^a   Li, Qiang ^a   Zhu, Sheng Yuan ^a   Li, Liang ^a   Xiong, Fu ^a   Jia, Yan Kai ^b   Xu, Xiang Min ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Philip Morris USA   (United States)

Author keywords

CYP2C9; Real time PCR; Tm shift genotyping; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; MENADIONE EPOXIDE; WARFARIN;

ARTICLE; COST BENEFIT ANALYSIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA POLYMORPHISM; DNA SEQUENCE; DOSE RESPONSE; GENE AMPLIFICATION; GENOTYPE; HEREDITY; MELTING POINT; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORESCENT DYES; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MIXED FUNCTION OXYGENASES; ORGANIC CHEMICALS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSITION TEMPERATURE; WARFARIN;

EID: 58149234043     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.008     Document Type: Article

References (22)

1. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007;7:99-111.
2. Loebstein R, Yonath H, Peleg D, Poller L, Bussey H, Ansell J, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 2001;70:159-64.
3. Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 2003;3:202-14.
4. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-8.
5. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23-34.
6. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-7.
7. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-9.
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
9. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005;106:135-40.
10. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33.
11. Tham LS, Goh BC, Nafziger A, Guo JY, Wang LZ, Soong R, et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 2006;80:346-55.
12. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007;63:1135-41.
13. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006;80:169-78.
14. Wen SY, Wang H, Sun OJ, Wang SQ. Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 2003;9:1342-6.
15. Hiratsuka M, Agatsuma Y, Omori F, Narahara K, Inoue T, Kishikawa Y, et al. High throughput detection of drug-metabolizing enzyme polymorphisms by allele-specific fluorogenic 5′ nuclease chain reaction assay. Biol Pharm Bull 2000;23:1131-5.
16. Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. Ther Drug Monit 2000;22:237-44.
17. Huang Y, Yang JF, Qi XL, Wang YQ, Wang WZ, Chen B. Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration. Zhonghua Yi Xue Za Zhi 2004;84:1686-9.
18. Toriello M, Meccariello P, Mazzaccara C, Di Fiore R, Esposito C, Sacchetti L. Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms. Clin Chem Lab Med 2006;44:285-7.
19. Papp AC, Pinsonneault JK, Cooke G, Sadée W. Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. Biotechniques 2003;34:1068-72.
20. m-shift primers. Biotechniques 2005;39:885-93.
21. Li L, Mo QH, Xu XM. Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC. Clin Chem Lab Med 2005;43:1334-8.
22. Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007;98:570-8.